Agenus Showcases Phase II Cancer Immunotherapy Data at AACR
LEXINGTON, Mass., April 3, 2026 Agenus Inc. has announced that new data from its Phase II clinical study evaluating...
Phase 2 study
Advertisement
Atom Therapeutics Advances ABP-745 into Phase 2 ASCVD Trial
December 16, 2025 – Cambridge, Massachusetts — Atom Therapeutics has announced the initiation of a multi-regional Phase 2 clinical...
Kiora Secures New U.S. Patent Expanding KIO-104 Formulation Options
Encinitas, California — December 1, 2025 — Kiora Pharmaceuticals has been granted a new U.S. patent (US-12,472,263) covering additional...
Halia Therapeutics’ Ofirnoflast Gains FDA Orphan Drug Status for MDS
LEHI, Utah, Oct. 23, 2025 — Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on therapies targeting the root...
Crinetics Unveils Neuroendocrine Tumour Data at NANETS 2025
SAN DIEGO / Austin, Texas – October 23, 2025 Crinetics Pharmaceuticals, Inc. announced new results at the 2025 North...
Advertisement
